Role of Interleukin-8 with Special Progress of Atopic Dermatitis


  • Muhammad Noman Khan Henan Provincial people’s Hospital, Zhengzhou, Henan, P. R. China



Interleukin-8, atopic dermatitis, cytokines, T lymphocytes


Atopic dermatitis (AD) is a recurrent pruritic chronic inflammatory skin disease, also known as atopic eczema and neurodermatitis sown. Its actual cause is still unknown, but association of disease progression may be related to immune system abnormalities. Many studies reported that AD lesions are linked with mainly increased no. of T lymphocytes with other inflammatory cells including monocytes, eosinophils and macrophages. T Lymphpocytes mediate inflammation and local immune response by secondary antibody production which are involved in cell-mediated immunity and delayed type hypersensitivity inflammatory reactions. IL-8 which is a proinflammatory cytokine and have high chemotactic activity on neutrophils, T lymphocytes and basophils along with activation of proinflammatory cells to perform immune functions. High expression of IL-8 was also reported in AD lesions which can cause chemotaxis, aggregation and activation of inflammatory cells. It also promotes IL-4 and IL-3 overexpression resulting in the proliferation and differentiation of mast cells which further aggravates AD. Here, in this manuscript IL-8 and related cytokines involved in atopic dermatitis pathogenesis and progression are reviewed more than spring season in dogs.


Guttman-Yassky E, Nograles K E, Krueger J G, Contrasting pathogenesis of atopic dermatitis and psoriasis-part Ⅰ: clinical and pathologic concepts. J Allergy Clin Immunol, 2011, 127(5):1110-1118.

Leung D Y, New insights into atopic dermatitis: role of skin barrier and immune dysregulation. Allergol Int, 2013, 62(2):151-161.

Hanifin JM, Chan S. Biochemical and immunologic emerging therapies. J Am Acad Dermatol, 1999, 41(1):72-77.

Schmidt E, Reimer S, Kruse N, et al Auto-antibodies to BP180 associated with bullous pemphigoid release IL-6 and IL-8 from cultured human keratinocytes. J Invest Dermatol 2000, 115:842-848.

Mc Pherson T. Current Understanding in Pathogenesis of Atopic Dermatitis. Indian J Dermatol. 2016, 61(6):649-655.

Murata S, Kaneko S, Morita E. Interleukin-8 Levels in the Stratum Corneum as a Biomarker for Monitoring Therapeutic Effect in Atopic Dermatitis Patients. Int Arch Allergy Immunol 2021, 182:592-606.

Kim KH Overview of atopic dermatitis. Asia Pac Allergy, 2013, 3(2):79-87.

Howell MD, Kim BE, Gao P, et al. Cytokine modulation of atopic dermatitis filaggrin skin expression. J Allergy Clin Immunol, 2009,124(3 Suppl 2):7-12.

Hu Y, Liu S, Liu P, Mu Z, Zhang J. Clinical relevance of eosinophils, basophils, serum total IgE level, allergen-specific IgE, and clinical features in atopic dermatitis. J Clin Lab Anal, 2020, 34(6):e23214.

Remick GD. Interleukin-8. Crit Care Med, 2005, 33(12 Suppl):5646-5647.

Waugh DJ, Wilson C. The interleukin-8 pathway in cancer. Clin Cancer Res, 2008,14(21):6735-6741.

Standiford TJ, Kunkel SL, Basha MA, et al. Interleukin-8 gene expression by a pulmonary epithelial cell line.A model for cytokine networks in the lung. J Clin Invest, 1990,86(6):1945-1953.

Holmes WE, Lee J, Kuang WJ, et al. Structure and functional expression of a human interleukin-8 receptor. Science, 1991, 253(5025):1278-1280.

Xiong X, Liao X, Qiu S, et al. CXCL8 in Tumor Biology and Its Implications for Clinical Translation. Front Mol Biosci, 2022, 9:723846.

Rose MS, Shukkur MF, John RG, et al. The functional significance behind expressing two IL-8 receptor types in PMN. J Leukoc Biol, 2009, 86(3):529-543.

Jinzhou Z, Jiannan H, Daopeng D, et al. Recombinant human interleukin-1 receptor antagonist treatment protects rats from myocardial ischemia reperfusion injury. Biomed & Pharmacother, 2019, 111:1-5.

Patti G, A. D’Ambrosio, Mega S, Giorgi G, et al. Early interleukin-1 receptor antagonist elevation in patients with acute myocardial infarction. J Am Coll Cardiol, 2004, 43, 35-38.

Gimbrone MA Jr, Obin MS, Brick AF, et al. Endothelial interleukin-8: a novel inhibitor of leukocyte-endothelial interactions. Science, 1989, 246(4937):1601-1603.

Khan MN, Wang B, Wei J, et al. CXCR1/2 antagonism with CXCL8/Interleukin-8 analogue CXCL8(3-72)K11R/G31P restricts lung cancer growth by inhibiting tumor cell proliferation and suppressing angiogenesis. Oncotarget, 2015, 28(25):21315-27.

Hanifin JM, Chan S. Biochemical and immunologic mechanisms in atopic dermatitis:new targets for emerging therapies. J Am Acad Dermatol, 1999,41(1):72-77.

Li L, Khan MN, Li Q, Chen X, et al. G31P, CXCR1/2 inhibitor, with cisplatin inhibits the growth of mice hepatocellular carcinoma and mitigates high- dose cisplatin-induced nephrotoxicity. Oncol Rep, 2015, 33(2):751-757.




How to Cite

Khan, M. N. (2023). Role of Interleukin-8 with Special Progress of Atopic Dermatitis. BioSight, 4(1), 99–103.